在帕金森病中致病性α-Synuclein变异V15A的表征
Sokhna Haissatou Diaw1, Max Borsche1,2, Linn Streubel-Gallasch1
1Institute of Neurogenetics, University of Lübeck, 23562, Lübeck, Germany.
NPJ Parkinson's disease
|October 31, 2023
概括
这项研究研究了一种与帕金森病相关的新型α-Synuclein (α-Syn) 变体 (p.V15A). 该变体促进α-Syn聚合和细胞功能障碍,支持其致病作用.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 细胞生物学 细胞生物学
背景情况:
- 阿尔法-同核素 (α-Syn) 是神经退行性疾病中莱维体的关键组成部分.
- 在SNCA基因中的致病变异很少见,只有四种错误变异最终与疾病有关.
研究的目的:
- 在帕金森病患者中发现的一种新型SNCA变异 (p.V15A) 的特征,该变异是在早期认知衰退的帕金森病患者中发现的.
- 阐明p.V15A变异对α-Syn.的功能和聚合影响.
主要方法:
- 使用的细胞模型:SH-SY5Y神经母细胞瘤细胞和诱导多能干细胞 (iPSC) 衍生的神经元.
- 创建了一个Drosophila melanogaster模型来评估体内效应.
- 将p.V15A与已知的致病性α-Syn变体进行比较.
主要成果:
- 这种p.V15A变种显著增加了α-Syn聚合潜力.
- 在细胞模型中观察到升高的亡标志物和受损的线粒体网络.
- 在突变的Drosophila中表现出降低的飞行能力和生存率.
结论:
- p.V15A变种显示出强有力的致病性证据,有助于α-Syn聚合和细胞损伤.
- 应考虑将这种变异纳入帕金森病遗传测试中.
更多相关视频
12:01Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein
Published on: May 30, 2015
10.8K
09:27Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains
Published on: January 5, 2016
17.4K
相关概念视频
Parkinson's Disease: Overview
567
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
567
Neural Regulation
39.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.5K
Amyloid Fibrils
9.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.6K
Parkinson's Disease: Treatment
281
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
281
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
Alzheimer's Disease: Overview
500
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
500
